Search

Your search keyword '"Devos D"' showing total 794 results
Start Over Author "Devos D"
794 results on '"Devos D"'

1. Quantitative brainstem and spinal MRI in amyotrophic lateral sclerosis: implications for predicting noninvasive ventilation needs

Author

Khamaysa, M., Lefort, M., Pélégrini-Issac, M., Lackmy-Vallée, A., Mendili, M. M. El, Preuilh, A., Devos, D., Bruneteau, G., Salachas, F., Lenglet, T., Amador, Md. M., Le Forestier, N., Hesters, A., Gonzalez, J., Rolland, A.-S., Desnuelle, C., Chupin, M., Querin, G., Georges, M., Morelot-Panzini, C., Marchand-Pauvert, V., and Pradat, P.-F.

Published
2024
Full Text
View/download PDF

8. Crosschecking the subjective everyday Parkinson's experience among patients and their caregiving spouses: French versions of the Belastungsfragebogen Parkinson Kurzversion (Bela-P-k and Bela-A-k)

Author

Bayen, S., primary, Heutte, J., additional, Vanderbecken, J.-C., additional, Moreau, C., additional, Defebvre, L., additional, Billot, R., additional, Guiton, V., additional, Lemey, C., additional, Lingner, H., additional, Messaadi, W., additional, Devos, D., additional, and Messaadi, N., additional

Published
2023
Full Text
View/download PDF

10. Contributors

Author

Abboud, Hesham, primary, Abdelkader, Noha F., additional, Abellanas, Miguel A., additional, Adams, Warwick R., additional, Airavaara, Mikko, additional, Al-Busaidi, Ibrahim S., additional, Alamri, Yassar, additional, Alberico, Stephanie L., additional, Alexiou, Athanasios, additional, Almeida, Lorena Rosa S., additional, Anderton, Ryan S., additional, Antipova, Veronica, additional, Aragona, Emanuela, additional, Arrigo, Alessandro, additional, Ashraf, Ghulam Md, additional, Auffret, Manon, additional, Aymerich, Maria S., additional, Bakeberg, Megan, additional, Barnes, Graham R., additional, Belbasis, Lazaros, additional, Bellou, Vanesa, additional, Benedetti, Fabrizio, additional, Benson, Patrick, additional, Bergantin, Leandro Bueno, additional, Bhidayasiri, Roongroj, additional, Bortolanza, Mariza, additional, Byrnes, Michelle, additional, Calamuneri, Alessandro, additional, Caricati-Neto, Afonso, additional, Carlino, Elisa, additional, Chaudhary, Sapana Sameer, additional, Chaudhary, Sameer, additional, Chmielarz, Piotr, additional, Chuproski, Ana Paula, additional, Del-Bel, Elaine, additional, De Risi, Marco, additional, Devedjian, J.C., additional, Devos, D., additional, Di Gennaro, Giancarlo, additional, Domanskyi, Andrii, additional, Dominico, Patrícia, additional, Drapier, Sophie, additional, Duce, J.A., additional, Dutta, Aloke K., additional, Eidelberg, David, additional, Evangelou, Evangelos, additional, Fagotti, Juliane, additional, Farotti, Lucia, additional, Fisichella, M., additional, Forjaz, Maria João, additional, Frisaldi, Elisa, additional, Fuermaier, Anselm B.M., additional, Fukushima, Kikuro, additional, Fukushima, Junko, additional, Gaeta, Michele, additional, Gordon, Luke, additional, Hawlitschka, Alexander, additional, Holzmann, Carsten, additional, Jansen, Josephien, additional, Januário, Cristina, additional, Jesus-Ribeiro, Joana, additional, Johnstone, Daniel M., additional, Koerts, Janneke, additional, Konovalova, Julia, additional, Kurth, Jens, additional, Lachaud, C., additional, Laloux, C., additional, Lanotte, Michele, additional, LeWitt, Peter A., additional, Lima, Marcelo M.S., additional, Lindner, Tobias, additional, Loewenbrück, K.F., additional, Lopiano, Leonardo, additional, Luo, Dan, additional, Mann, Teresa, additional, Mao, Peizhong, additional, Mao, Yifan, additional, Martinez–Martin, Pablo, additional, Mastaglia, Frank L., additional, Mizutani, Yasuaki, additional, Modugno, Nicola, additional, Moreau, C., additional, Mormina, Enricomaria, additional, Müller, Thomas, additional, Mutoh, Tatsuro, additional, Nagao, Kanae, additional, Narayanan, Nandakumar S., additional, Nascimento, Glauce Crivelaro, additional, Natesan, Saieswari, additional, Neilson, Lee, additional, Niimi, Yoshiki, additional, Olivola, Enrica, additional, Pan-Montojo, F., additional, Panhelainen, Anne, additional, Paolini Paoletti, Federico, additional, Pardeshi, Tanvee, additional, Parnetti, Lucilla, additional, Paul, Serene S., additional, Perovnik, Matej, additional, Petrucco, Claudia, additional, Piedimonte, Alessandro, additional, Rawat, Sakshi, additional, Reichmann, H., additional, Reith, Maarten, additional, Riley, Maddeson, additional, Rodríguez-Blázquez, Carmen, additional, Rožanković, Petra Bago, additional, Rus, Tomaž, additional, Sakakibara, Ryuji, additional, Santos-Lobato, Bruno L., additional, Scorza, Fúlvio Alexandre, additional, Stone, Jonathan, additional, Tang, Chris C., additional, Targa, Adriano D.S., additional, Tateno, Fuyuki, additional, Tomše, Petra, additional, Trošt, Maja, additional, Tsiang, John T.H., additional, Tucha, Lara, additional, Tucha, Oliver, additional, Uchiyama, Tomoyuki, additional, Valenca, Guilherme T., additional, Vérin, Marc, additional, Vieira, Daniela, additional, Willis, Gregory L., additional, Witt, Martin, additional, Woo, Benjamin K.P., additional, Wree, Andreas, additional, Yamamoto, Tatsuya, additional, Zande, Jonathan, additional, and Zibetti, Maurizio, additional

Published
2020
Full Text
View/download PDF

13. Indication for molecular testing by multiplex ligation‐dependent probe amplification in parkinsonism

Author

Mutez, E., primary, Swiderski, M., additional, Devos, D., additional, Moreau, C., additional, Baille, G., additional, Degardin, A., additional, Ryckewaert, G., additional, Carriere, N., additional, Kreisler, A., additional, Simonin, C., additional, Rouaix, N., additional, Tir, M., additional, Krystkowiak, P., additional, Ramdane, N., additional, Génin, M., additional, Sablonnière, B., additional, Defebvre, L., additional, and Huin, V., additional

Published
2023
Full Text
View/download PDF

15. Theme 09 - Clinical Trials and Trial Design.

Author

Katz, J., Vu, T., Chiò, A., McDermott, C., Devos, D., Gordon, G., Johnston, M., Maier, J., Trimmer, J., Tansy, A., Shefner, J., Angela Genge, A., Boggs, B., Ganti, R., Hinckley, S., Johnson, K., Kaneb, H., Polzer, J., Rubino, S., and Salmon, K.

Subjects
EXPERIMENTAL design, AMYOTROPHIC lateral sclerosis, LIBRARY users, RESEARCH personnel, LIBRARY resources
Abstract

The text is a report on clinical trials and trial design in the field of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD). It is authored by a large number of researchers and experts in the field. The report provides a comprehensive overview of ongoing clinical trials, trial design considerations, and potential future directions for research in ALS and FTD. It is a valuable resource for library patrons conducting research on these specific topics. [Extracted from the article]

Published
2023
Full Text
View/download PDF

25. Trial of Deferiprone in Parkinson's Disease

Author

Devos, D., Labreuche, J., Rascol, O., Corvol, J.C., Duhamel, A., Delannoy, P. Guyon, Poewe, W., Compta, Y., Pavese, N., Růžička, E., Dušek, P., Post, B., Bloem, B.R., Berg, D., Maetzler, W., Otto, M., Habert, M.O., Lehericy, S., Ferreira, J., Dodel, R., Tranchant, C., Eusebio, A., Thobois, S., Marques, A.R., Meissner, W.G., Ory-Magne, F., Walter, U., Bie, R.M. de, Gago, M., Vilas, D., Kulisevsky, J., Januario, C., Coelho, M.V.S., Behnke, S., Worth, P., Seppi, K., Ouk, T., Potey, C., Leclercq, C., Viard, R., Kuchcinski, G., Lopes, R., Pruvo, J.P., Pigny, P., Garçon, G., Simonin, O., Carpentier, J., Rolland, A.S., Nyholm, D., Scherfler, C., Mangin, J.F., Chupin, M., Bordet, R., Dexter, D.T., Fradette, C., Spino, M., Tricta, F., Ayton, S., Bush, A.I., Devedjian, J.C., Duce, J.A., Cabantchik, I., Defebvre, L., Deplanque, D., Moreau, C., Devos, D., Labreuche, J., Rascol, O., Corvol, J.C., Duhamel, A., Delannoy, P. Guyon, Poewe, W., Compta, Y., Pavese, N., Růžička, E., Dušek, P., Post, B., Bloem, B.R., Berg, D., Maetzler, W., Otto, M., Habert, M.O., Lehericy, S., Ferreira, J., Dodel, R., Tranchant, C., Eusebio, A., Thobois, S., Marques, A.R., Meissner, W.G., Ory-Magne, F., Walter, U., Bie, R.M. de, Gago, M., Vilas, D., Kulisevsky, J., Januario, C., Coelho, M.V.S., Behnke, S., Worth, P., Seppi, K., Ouk, T., Potey, C., Leclercq, C., Viard, R., Kuchcinski, G., Lopes, R., Pruvo, J.P., Pigny, P., Garçon, G., Simonin, O., Carpentier, J., Rolland, A.S., Nyholm, D., Scherfler, C., Mangin, J.F., Chupin, M., Bordet, R., Dexter, D.T., Fradette, C., Spino, M., Tricta, F., Ayton, S., Bush, A.I., Devedjian, J.C., Duce, J.A., Cabantchik, I., Defebvre, L., Deplanque, D., and Moreau, C.

Abstract

Item does not contain fulltext, BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. CONCLUSIONS: In parti

Published
2022

26. Subthalamic Nucleus Stimulation Modulates Motor Cortex Oscillatory Activity in Parkinson's Disease

Author

Devos, D., Labyt, E., and Derambure, P.

Abstract

In Parkinson's disease, impaired motor preparation has been related to an increased latency in the appearance of movement-related desynchronization (MRD) throughout the contralateral primary sensorimotor (PSM) cortex. Internal globus pallidus (GPi) stimulation improved movement desynchronization over the PSM cortex during movement execution but failed to improve impaired motor preparation. PET studies indicate that subthalamic nucleus (STN) stimulation partly reverses the abnormal premotor pattern of brain activation during movement. By monitoring MRD, we aimed to assess changes in premotor and PSM cortex oscillatory activity induced by bilateral STN stimulation and to compare these changes with those induced by L-dopa. Ten Parkinson's disease patients and a group of healthy, age-matched controls performed self-paced wrist flexions in each of four conditions: without either stimulation or L-dopa (the "off" condition), with stimulation and without L-dopa (On Stim), with L-dopa and without stimulation ("on drug"), and with both stimulation and L-dopa (On Both). Compared with the Off condition, in both the On Stim and the On Drug condition the Unified Parkinson's Disease Rating Scale (UPDRS) III score decreased by about 60% and in the On Both condition it decreased by 80%. The desynchronization latency over central regions contralateral to movement and the movement desynchronization over bilateral central regions were significantly increased by stimulation and by L-dopa, with a maximal effect when the two were associated. Furthermore, desynchronization latency significantly decreased over bilateral frontocentral regions in the three treatment conditions compared with the Off condition. In Parkinson's disease, STN stimulation may induce a change in abnormal cortical oscillatory activity patterns (similar to that produced by L-dopa) by decreasing the abnormal spreading of desynchronization over frontocentral regions and increasing PSM cortex activity during movement preparation and execution, with a correlated improvement in bradykinesia. Parkinsonians under treatment displayed a desynchronization pattern close to that seen in healthy, age-matched controls, although central latencies remained shorter. The study indicates that it is possible to influence cortical reactivity related to the planning and execution of voluntary movement through the basal ganglia, and furthermore that the oscillatory activity of the PSM cortex (in addition to that of premotor areas) could be of major importance in the control of movement-associated, neural activity in Parkinson's disease.

Published
2004

28. Joint latent class model:Simulation study of model properties and application to amyotrophic lateral sclerosis disease

Author

Kyheng, M. (MaÉva), Babykina, G. (Génia), Ternynck, C. (Camille), DEVOS, D. (DAVID), Labreuche, J. (Julien), Duhamel, A. (Alain), Université de Lille, CHU Lille, and Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Subjects
Amyotrophic lateral sclerosis, Joint model, Latent classes, Linear mixed model, MLE properties, Monte Carlo simulations, Survival analysis
Abstract

In many clinical applications, evolution of a longitudinal marker is censored by an event occurrence, and, symmetrically, event occurrence can be influenced by the longitudinal marker evolution. In such frameworks joint modeling is of high interest. The Joint Latent Class Model (JLCM) allows to stratify the population into groups (classes) of patients that are homogeneous both with respect to the evolution of a longitudinal marker and to the occurrence of an event; this model is widely employed in real-life applications. However, the finite sample-size properties of this model remain poorly explored. In the present paper, a simulation study is carried out to assess the impact of the number of individuals, of the censoring rate and of the degree of class separation on the finite sample size properties of the JLCM. A real-life application from the neurology domain is also presented. This study assesses the precision of class membership prediction and the impact of covariates omission on the model parameter estimates. Simulation study reveals some departures from normality of the model for survival sub-model parameters. The censoring rate and the number of individuals impact the relative bias of parameters, especially when the classes are weakly distinguished. In real-data application the observed heterogeneity on individual profiles in terms of a longitudinal marker evolution and of the event occurrence remains after adjusting to clinically relevant and available covariates; CONCLUSION: The JLCM properties have been evaluated. We have illustrated the discovery in practice and highlights the usefulness of the joint models with latent classes in this kind of data even with pre-specified factors. We made some recommendations for the use of this model and for future research. 21;1

Published
2021

34. Personality dimensions could be predictive of quality-of-life outcome after deep brain stimulation of the sub-thalamic nucleus in Parkinson's

Author

Boussac, M., Danaila, T., Eusebio, A., Hainque, E., Corvol, J. C., Rascol, O., Moreau, C., Rolland, A. S., Devos, D., Ansquer, S., Boukbiza, O. L., Marques, A. R., Maltete, D., Drapier, S., Jarraya, B., Belamri, L., Burbaud, P., Meyer, M., Rouaud, T., Giordana, B., Tir, Mélissa, Brefel-Courbon, C., Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Assistance Publique - Hôpitaux de Marseille (APHM), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Environnement, Ville, Société (EVS), École normale supérieure de Lyon (ENS de Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT), Laboratoire d'interaction du rayonnement X avec la matière (LIXAM), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021

37. Modifying effect of ceruloplasmin polymorphism on iron chelation response in Parkinsonʼs disease: 652

Author

Grolez, G., Meguig, S., Moreau, C., Sablonnière, B., Strubi-Vuilhaume, I., Ryckewaert, G., Jissendi, P., Hopes, L., Dujardin, K., Devedjian, J.-C., Kluza, J., Laloux, C., Jonneaux, A., Petrault, M., Garçon, G., Rouaix, N., Duhamel, A., Auger, F., Ravasi, L., Firdaus, W., Zahr, N., Destée, A., Corvol, J.-C., Pöltl, D., Leist, M., Rose, C., Marchetti, P., Cabantchik, I. Z., Bordet, R., Defebvre, L., and Devos, D.

Published
2014

42. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease

Author

Devos, D., Krystkowiak, P., Clement, F., Dujardin, K., Cottencin, O., Waucquier, N., Ajebbar, K., Thielemans, B., Kroumova, M., Duhamel, A., Destee, A., Bordet, R., and Defebvre, L.

Subjects
Parkinson's disease -- Care and treatment, Parkinson's disease -- Patient outcomes, Parkinson's disease -- Research, Methylphenidate -- Dosage and administration, Methylphenidate -- Research, Methylphenidate hydrochloride -- Dosage and administration, Methylphenidate hydrochloride -- Research, Gait -- Evaluation, Health, Psychology and mental health
Published
2007

43. Abnormal Aortic Wall Properties in Women with Turner Syndrome

Author

Bons, Lidia, Hoven, Allard, Malik, Maira, van den Bosch, Annemien, Mcghie, Jackie, Duijnhouwer, Anthonie, Siebelink, H-MJ, Hirsch, Alexander, Devos, D, Rietzschel, E, von der Thüsen, Jan, De Graaf - van de Laar, Ingrid, Verhagen, Judith, van der Pluijm, Ingrid, Budde, Ricardo, Roos - Hesselink, Jolien, Bons, Lidia, Hoven, Allard, Malik, Maira, van den Bosch, Annemien, Mcghie, Jackie, Duijnhouwer, Anthonie, Siebelink, H-MJ, Hirsch, Alexander, Devos, D, Rietzschel, E, von der Thüsen, Jan, De Graaf - van de Laar, Ingrid, Verhagen, Judith, van der Pluijm, Ingrid, Budde, Ricardo, and Roos - Hesselink, Jolien

Published
2020

45. A specific clinical pattern of camptocormia in Parkinson's disease

Author

Lepoutre, A.-C., Devos, D., Blanchard-Dauphin, A., Pardessus, V., Maurage, C.-A., Ferriby, D., Hurtevent, J.-F., Cotten, A., Destee, A., and Defebvre, L.

Subjects
Parkinson's disease -- Research, Parkinson's disease -- Physiological aspects, Parkinson's disease -- Development and progression, Posture disorders -- Causes of, Posture disorders -- Research, Health, Psychology and mental health
Published
2006

46. Aortic reflection coefficients and their association with global indexes of wave reflection in healthy controls and patients with Marfan's syndrome

Author

Segers, P., De Backer, J., Devos, D., Rabben, S.I., Gillebert, T.C., Van Bortel, L.M., De Sutter, J., De Paepe, A., and P.R., Verdonck

Subjects
Magnetic resonance imaging -- Usage, Magnetic resonance imaging -- Analysis, Marfan syndrome -- Research, Marfan syndrome -- Diagnosis, Biological sciences
Abstract

Early return of reflected pressure waves increases the load on central arteries and may increase the risk of aortic rupture in patients with Marfan's syndrome (MFS). To assess whether wave reflection is elevated in MFS, we used ultrasound and MRI to measure central pressure and flow waveforms in 26 patients (13-54 yr of age) and 26 age- and gender-matched controls. Aortic systolic and diastolic cross-sectional areas were measured at the ascending and descending aorta (AA and DA), diaphragm (DIA), and lower abdominal aorta (AB). From these measurements, local characteristic impedance ([Z.sub.0-xx]) and local reflection coefficients ([T.sub.xx-yy]) were calculated. Calculated global wave reflection indexes were the augmentation index (AIx) and the ratio of backward to forward pressure wave ([P.sub.b]/[P.sub.f]). The aorta was wider in MFS patients at AA (P < 0.01) and DA (P < 0.01). Aortic pulse wave velocity was 42 cm/s higher in MFS patients (P < 0.05). [Z.sub.0-xx], was not different between groups, except at DA, where it was lower in MFS patients. In controls, [[GAMMA].sub.AA-DA] was 0.31 [+ or -] 0.08, [[GAMMA].sub.DA-DIA] was 0.00 [+ or -] 0.11, and [[GAMMA].sub.DIA-AB] was 0.31 [+ or -] 0.16. Mean values of [[GAMMA].sub.xx-yy] were not different between MFS patients and controls. In controls, aging diminished [[GAMMA].sub.AA-DA] but increased [[GAMMA].sub.DIA-AB]. Clear age-related patterns were absent in MFS patients. AIx or [P.sub.b]/[P.sub.f] was not higher in MFS patients than in controls. There were indications for enhanced wave reflection in young MFS patients. Our data demonstrated that the major determinants of AIx were pulse wave velocity and the effective length of the arterial system and, to a lesser degree, HR and [P.sub.b]/[P.sub.f]. magnetic resonance imaging; augmentation index

Published
2006

47. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease

Author

Sockeel, P., Dujardin, K., Devos, D., Deneve, C., Destee, A., and Defebvre, L.

Subjects
Parkinson's disease -- Research, Parkinson's disease -- Diagnosis, Neuropsychological tests -- Research, Apathy -- Diagnosis, Neurologic manifestations of general diseases -- Diagnosis, Neurologic manifestations of general diseases -- Research, Health, Psychology and mental health
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results